argenx to acquire Unnatural Products for up to $1.15 billion
argenx announced a definitive agreement to buy private biotech Unnatural Products (UNP). The transaction includes a $550 million cash payment up‑front and up to $595 million in milestone payments, bringing total consideration to about $1.15 billion. The deal is expected to close by the end of 2026, subject to customary conditions, and UNP will remain operating from its Santa Cruz site as a peptide‑discovery hub within argenx.
Why it matters
The acquisition adds a macrocyclic peptide platform to argenx’s antibody engineering, expanding its pipeline options for oral and long‑acting immunology therapies (the company says). The transaction will increase argenx’s cash outflow by $550 million now and may require additional milestone payments later.
Key facts
- 1Up‑front cash payment of $550 million. quantisnow.com
- 2Potential milestone payments of up to $595 million, for a total possible value of about $1.15 billion. pharmexec.com
- 3Closing expected by the end of 2026, subject to customary closing conditions. citybiz.co
- 4Unnatural Products will continue to operate from its Santa Cruz, California facility as a dedicated macrocyclic peptide discovery hub within argenx. citybiz.co
- 5UNP employs more than 50 people. citybiz.co
Summary written by AlphAI AI Desk from 15 of 15 sources. Not investment advice. Figures are as stated by the linked sources.